Question · asked by 1 review
Intratympanic gentamicin vs no treatment/placebo: Vertigo (global score) at < 3 months
- Population
- Ménière’s disease
- Intervention
- Intratympanic gentamicin
- Comparison
- no treatment/placebo
- Outcome
- Vertigo (global score) at < 3 months
What each review found
Include earlier review versionsNo studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Intratympanic gentamicin vs no treatment/placebo Vertigo (global score)Scale from: 0 (none) to 3 (severe) · Ménière’s disease Intratympanic gentamicin for Ménière’s disease (2023) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 26 participants | Very low |
Intratympanic gentamicin vs no treatment/placebo Vertigo (global score) Scale from: 0 (none) to 3 (severe) · Ménière’s disease Intratympanic gentamicin for Ménière’s disease (2023) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 26 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.